baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

LUPIN LIMITED Stock/ INE326A01037 /

6/10/2024 6:50:38 AM	Chg. +1.70	Volume	Bid6/10/2024	Ask6/10/2024	High	Low
1,631.25INR	+0.10%	320,539 Turnover: 526.33 mill.	1,631.20Bid Size: 19	1,631.40Ask Size: 18	1,660.00	1,625.15

GlobeNewswire 2/9/2022 Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla®

GlobeNewswire 11/4/2021 Lupin’s Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adult...

GlobeNewswire 2/16/2021 Lupin responds to NICE Appraisal Consultation Document (ACD) on NaMuscla® (mexiletine) to treat symp...

GlobeNewswire 12/8/2020 Scottish Medicines Consortium approves Lupin's NaMuscla® (mexiletine) to treat symptomatic myotonia ...

GlobeNewswire 6/8/2020 US FDA Grants Mexiletine Orphan Drug Designation

GlobeNewswire 6/3/2020 Lupin signs distribution agreements in key EU territories for orphan drug NaMuscla®

GlobeNewswire 2/1/2019 Lupin Announces Launch of Orphan Drug NaMuscla® in Germany and the UK for the Treatment of Myotonia ...

GlobeNewswire 1/8/2019 Lupin Limited: Orphan Drug NaMuscla® Receives European Commission Approval for the Treatment of Myot...

LUPIN LIMITED Stock/ INE326A01037 /

If you wish to receive reply to your feedback, please provide your email address.